Drug Profile
RR 1
Alternative Names: RR-1; RR1 - Dharma BiomedicalLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Dharma Biomedical
- Class Antineoplastics; Polysaccharides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 13 Jul 2016 RR 1 is available for licensing as of 13 Jul 2016. http://www.dharmabiomedical.com
- 13 Jul 2016 Preclinical trials in Cancer in USA (unspecified route)